NicOx gets $10m boost as B+L starts glaucoma Phase III
This article was originally published in Scrip
Executive Summary
Bausch & Lomb is to pursue a global Phase III development programme for BOL-303259-X, a novel nitric oxide-donating prostaglandin F2-alpha analogue, in patients with open-angle glaucoma or ocular hypertension, after the company and NicOx reported that the product had met the primary endpoint in a Phase IIb study, triggering a $10 million milestone payment to NicOx.